Last $57.46 USD
Change Today +0.25 / 0.44%
Volume 5.1M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$57.29
Previous Close
$57.21
Day High
$57.86
Day Low
$57.25
52 Week High
12/8/14 - $62.20
52 Week Low
01/2/14 - $49.30
Market Cap
163.8B
Average Volume 10 Days
11.9M
EPS TTM
$3.45
Shares Outstanding
2.9B
EX-Date
12/11/14
P/E TM
16.6x
Dividend
$1.80
Dividend Yield
3.08%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Merck & Co. Inc. Announces Executive Changes

Merck has appointed Anand Nambiar as managing director replacing Claus-Dieter Boedecker who resigned, as per a public disclosure. Claus-Dieter Boedecker has resigned as he plans to relocate to Germany, his home country, and requested the firm's board to relieve him from his responsibilities by January 31, 2015. Anand Nambiar has been working as managing director of Optronics Division at AZ Electronic Materials.

Merck Announces Encouraging Data from Breast Cancer Study

Merck has announced early study findings demonstrating an overall response rate of 18.5% with KEYTRUDA, the company's anti-PD-1 therapy, as assessed by RECIST v1.1, central review, or n=5/27, in PD-L1 positive, advanced triple-negative breast cancer. At the time of analysis, the median duration of response had not been reached with three of five responders on therapy for 11 months or more (range, 15 to 40+ weeks). Phase II study planned for the first half of 2015 will be an important next step for breast cancer clinical program. Data presented were from a cohort of the ongoing Phase Ib KEYNOTE-012 study which evaluated KEYTRUDA monotherapy at 10 mg/kg every two weeks in patients with advanced TNBC whose tumors were determined to be positive for PD-L1 expression (n=32). As measured by Merck's proprietary PD-L1 immunohistochemistry (IHC) clinical trial assay, tumors were considered to be PD-L1 positive if staining was present in the stroma or in greater than or equal to 1% of tumor cells. In the study, 58 % of patients screened had tumors determined to be positive for PD-L1 expression. Most patients enrolled in this study had received two or more prior chemotherapies for metastatic disease and 87.5 % had received prior neo-adjuvant or adjuvant therapy. The median time to response was 18 weeks (range, 7-32 weeks). In the study, 33 % of patients with KEYTRUDA achieved tumor shrinkage. At six months, the progression-free survival rate with KEYTRUDA was 23.3 %. Adverse events were consistent with previously reported safety data for KEYTRUDA. The most common treatment-related adverse events (occurring in greater than or equal to five % of patients) included arthralgia (n=6), fatigue (n=6), myalgia (n=5), nausea (n=5), ALT increased (n=2), AST increased (n=2), diarrhea (n=2), erythema (n=2) and headache (n=2). Grade 3-5 treatment-related adverse events occurred in a total of five patients and included anemia, disseminated intravascular coagulation (DIC), headache, meningitis aseptic, decreased blood fibrinogen, and pyrexia. Two patients discontinued KEYTRUDA due to adverse events. One treatment-related death was reported in a patient with rapidly progressive disease and was due to DIC with thrombocytopenia and decreased blood fibrinogen. KEYNOTE-012 is an ongoing multi-center, non-randomized Phase Ib trial evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy in patients with advanced triple-negative breast cancer (TNBC), advanced head and neck cancer, advanced urothelial (bladder) cancer, or advanced gastric cancer. The primary endpoints of the study include overall safety, tolerability and anti-tumor activity (as measured by RECIST v1.1 assessed by independent radiology review) in PD-L1 positive tumors; secondary endpoints include progression-free survival (PFS), overall survival (OS) and duration of response. In 2014, early findings were presented for all four cohorts of the Phase Ib KEYNOTE-012 study.

Merck & Co. Inc. Receives Approval for an Updated Version of Gardasil Vaccine

Merck & Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The Food and Drug Administration approved the company's Gardasil 9, which protects against nine strains of the virus called HPV, or human papillomavirus. That's up from four strains covered by the original Gardasil vaccine approved in 2006. The FDA announced the updated Gardasil has the potential to prevent roughly 90% of cervical, vulvar, vaginal and anal cancers. Original Gardasil protected against strains blamed for 70% of U.S. cervical cancers. Like its predecessor, Gardasil 9 also guards against two viral strains that cause genital warts. About 75 to 80% of men and women are infected with HPV during their lifetime. Most don't develop symptoms and clear it on their own. But some infections lead to genital warts, cervical cancer and other cancers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $57.46 USD +0.25

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $166.96 USD +0.09
Bayer AG €114.86 EUR -0.61
Gilead Sciences Inc $91.29 USD +1.84
L'Oreal SA €138.35 EUR -1.50
Roche Holding AG SFr.270.10 CHF -3.20
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 31.4x
Price/Sales 3.8x
Price/Book 3.6x
Price/Cash Flow 30.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.